Mink Therapeutics, Inc. (INKT)

$0.9658

Market is closed - opens 7 PM, 14 Jun 2024

Insights on Mink Therapeutics, Inc.

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 11.70B → -11.70B (in $), with an average decrease of 200.0% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, -5.45M → -3.81M (in $), with an average increase of 43.2% per quarter

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 81.8% return, outperforming this stock by 139.7%

Performance

  • $0.96
    $0.98
    $0.97
    downward going graph

    1.34%

    Downside

    Day's Volatility :2.52%

    Upside

    1.19%

    downward going graph
  • $0.75
    $3.34
    $0.97
    downward going graph

    22.68%

    Downside

    52 Weeks Volatility :77.54%

    Upside

    70.96%

    downward going graph

Returns

PeriodMink Therapeutics, Inc.Sector (Health Care)Index (Russel 2000)
3 Months
5.96%
-0.3%
0.0%
6 Months
-8.17%
7.4%
0.0%
1 Year
-57.9%
11.0%
0.0%
3 Years
-91.96%
17.3%
-24.3%

Highlights

Market Capitalization
39.0M
Book Value
- $0.58
Earnings Per Share (EPS)
-0.59
Wall Street Target Price
8.0
Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
-111.24%
Return On Equity TTM
-1238.98%
Revenue TTM
0.0
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
0.0%
Gross Profit TTM
0.0
EBITDA
-20.7M
Diluted Eps TTM
-0.59
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-0.4
EPS Estimate Next Year
-0.44
EPS Estimate Current Quarter
-0.15
EPS Estimate Next Quarter
-0.13

Analyst Recommendation

Buy
    90%Buy
    10%Hold
    0
    0%Sell
Based on 10 Wall street analysts offering stock ratings for Mink Therapeutics, Inc.(by analysts ranked 0 to 5 stars)
Based on 10 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
9
9
9
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 728.33%

Current $0.97
Target $8.00

Technicals Summary

Sell

Neutral

Buy

Mink Therapeutics, Inc. is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Mink Therapeutics, Inc.
Mink Therapeutics, Inc.
-1.59%
-8.17%
-57.9%
-91.96%
-91.96%
Moderna, Inc.
Moderna, Inc.
17.55%
87.94%
15.42%
-28.78%
814.11%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
5.19%
17.3%
33.92%
94.36%
234.29%
Novo Nordisk A/s
Novo Nordisk A/s
8.19%
44.85%
81.77%
239.36%
454.2%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
10.67%
17.46%
39.08%
144.25%
181.72%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Mink Therapeutics, Inc.
Mink Therapeutics, Inc.
NA
NA
NA
-0.4
-12.39
-1.11
NA
-0.58
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.19
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
29.82
29.82
1.46
44.13
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
49.58
49.58
2.36
3.48
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
31.23
31.23
0.53
17.08
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Mink Therapeutics, Inc.
Mink Therapeutics, Inc.
Buy
$39.0M
-91.96%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$56.6B
814.11%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$111.3B
234.29%
29.82
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$636.1B
454.2%
49.58
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$124.3B
181.72%
31.23
39.46%

Institutional Holdings

  • Vanguard Group Inc

    0.59%
  • Longbow Finance SA

    0.42%
  • Renaissance Technologies Corp

    0.23%
  • Geode Capital Management, LLC

    0.23%
  • BlackRock Inc

    0.19%
  • CapTrust Financial Advisors

    0.14%

Company Information

Organization
Mink Therapeutics, Inc.
Employees
31
CEO
Dr. Garo H. Armen Ph.D.
Industry
Services

FAQs